Description

PT-141, designated chemically as bremelanotide, represents a synthetic cyclic heptapeptide developed as an analogue of Œ±-melanocyte stimulating hormone with enhanced selectivity and stability characteristics. The compound is structurally related to melanotan II but incorporates specific modifications designed to improve selectivity for melanocortin-4 receptors while reducing activity at melanocortin-1 receptors. The peptide functions as a melanocortin receptor agonist, demonstrating high binding affinity for melanocortin-4 receptors located in the central nervous system. Activation of these receptors leads to stimulation of adenylyl cyclase and increased cyclic adenosine monophosphate (cAMP) levels, triggering downstream signaling cascades that influence various physiological processes. PT-141’s cyclic structure contributes to enhanced stability compared to linear peptide analogues, making it suitable for various research protocols examining melanocortin biology. For research use only.